Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
Zhang, Pin, Prof, Sun, Tao, Prof, Zhang, Qingyuan, Prof, Yuan, Zhongyu, Prof, Jiang, Zefei, Prof, Wang, Xiao Jia, Prof, Cui, Shude, Prof, Teng, Yuee, Prof, Hu, Xi-Chun, Prof, Yang, Junlan, Prof, Pan, Hongming, Prof, Tong, Zhongsheng, Prof, Li, Huiping, Prof, Yao, Qiang, Prof, Wang, Yongsheng, Prof, Yin, Yongmei, Prof, Sun, Ping, Prof, Zheng, Hong, Prof, Cheng, Jing, Prof, Lu, Jinsong, Prof, Zhang, Baochun, MD, Geng, Cuizhi, Prof, Liu, Jian, Prof, Peng, Roujun, MD, Yan, Min, MD, Zhang, Shaohua, MD, Huang, Jian, MD, Tang, Li, PhD, Qiu, Rongguo, PhD, Xu, Binghe, Prof
Published in The lancet oncology (01.03.2017)
Published in The lancet oncology (01.03.2017)
Get full text
Journal Article